Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

Increased stress hormones accelerate breast cancer metastasis

It has long been thought that stress contributes to cancer progression. Scientists from the University of Basel and the University Hospital of Basel have deciphered the molecular mechanisms linking breast cancer metastasis with increased stress hormones.

14 Mar 2019

Hypertension drug may improve effectiveness of ovarian cancer treatment

A new study from a Massachusetts General Hospital research team has found that the hypertension drug losartan, which targets the angiotensin signaling pathway, may improve the effectiveness of chemotherapy agents used to treat ovarian cancer

16 Jan 2019

Clinigen, Accord Healthcare extend exclusive European clinical trial supply agreement

Clinigen Group plc, the global pharmaceutical and services company, announces that its Clinical Trial Service business has extended its exclusive European clinical trial supply agreement with Accord Healthcare. Clinigen is also offering pharma companies an ‘on demand’ service to Accord’s products, a first for the industry.

From Clinigen Group 11 Jan 2019

Study uncovers how tumors backfire on neoadjuvant chemotherapy

Some patients with breast cancer receive chemotherapy before the tumor is removed with surgery. This approach, called 'neoadjuvant' therapy, helps to reduce the size of the tumor to facilitate breast-conserving surgery, and can even eradicate the tumor, leaving few or no cancerous cells for the surgeon to remove.

2 Jan 2019

Study assesses safety and efficacy of new treatment for pancreatic cancer

Gemcitabine given in combination with nab-paclitaxel is the standard of care for patients with advanced pancreatic cancer. This practice, however, rests on data obtained from several recent clinical trials enrolling patients with pancreatic cancer who skewed younger and in better overall condition than most.

13 Dec 2018

New substance could improve efficacy of established breast cancer treatments

Physicians from Karl Landsteiner University of Health Sciences in Krems (Austria) demonstrate potential for clinical application, collaborating with research groups from Germany, the USA, and China.

13 Dec 2018

Two genomic tests help identify most effective treatment for breast cancer patients

New results from a long-running trial to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, show that two genomic tests are bringing the era of truly personalized medicine ever nearer.

14 Nov 2018

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Patients with an aggressive form of advanced breast cancer can benefit from immunotherapy when used in combination with chemotherapy as first-line treatment, according to the results of a large international Phase III clinical trial published today in the New England Journal of Medicine and led by a researcher at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine.

23 Oct 2018

Study findings could set new standard of care for advanced anal cancer

A new approach to treating advanced anal cancer is safer and more effective than the most widely used current treatment, according to the first ever randomized clinical trial in this group of patients.

22 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Immunotherapy improves survival in some patients with metastatic triple negative breast cancer, according to late-breaking results from the IMpassion130 trial reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

Immunotherapy trial offers new hope for people with aggressive breast cancer

There is new hope for people with an aggressive type of breast cancer, as an immunotherapy trial shows for the first time that lives can be extended in people with triple-negative breast cancer.

22 Oct 2018

Breast cancer survival could be extended with two new drug combinations

A new study has shown that a combination of drugs palbociclib, along with hormone therapy can significantly increase the survival among women with advanced breast cancer.

21 Oct 2018

Two major studies on canine cancers may provide clues on human cancers

Two studies into deadly cancers in dogs are now underway, offered through the newly formed Clinical Trials Office at Cummings Veterinary Medical Center at Tufts University. Dogs with spontaneous osteosarcoma, as well as dogs with mast cell tumors and solid tumors, may be eligible for enrollment.

12 Oct 2018

Study: Chemotherapy drugs may promote muscle mitochondrial dysfunction

Chemotherapy drugs to treat breast cancer may promote muscle mitochondrial dysfunction, according to new research. Dysfunctional mitochondria, the energy centers of the cells, may contribute to fatigue and weakness that some people with breast cancer experience through the course of disease treatment.

5 Oct 2018

Researchers take first steps in developing 'paintable' chemotherapy for melanoma

Skin acts as the first line of defense against pathogens and other harmful material from outside the body. Yet this barrier also excludes some beneficial drugs that could treat skin diseases.

26 Sep 2018

Researchers discover novel targeting agents to prevent cancer metastasis

Recently, a research team led by Maurizio Pellecchia at the University of California, Riverside, discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

26 Sep 2018

FDA approves new 5 mm diameter drug-eluting stent from Cook Medical

Cook Medical announced that a new 5 mm diameter version of Zilver® PTX® was approved by the FDA. It is the first 5 mm drug-eluting stent in the U.S. with lengths available up to 140 mm that is indicated to treat vessels as small as 4mm in diameter.

25 Sep 2018

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a clinical-stage rare disease and oncology company focused on sourcing and developing innovative treatments for underserved patient populations, announced today that the companies have entered into a global clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene's investigational RAF dimer inhibitor, lifirafenib and SpringWorks Therapeutics' investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors.

6 Sep 2018

Researchers develop better options to treat peripheral artery disease

Cristina Sabliov, LSU Biological and Agricultural Engineering professor, and Tammy Dugas, professor in the LSU School of Veterinary Medicine's Department of Comparative Biomedical Sciences, have joined forces to fight peripheral artery disease, or PAD, an ailment affecting 8 million Americans.

29 Aug 2018

Paclitaxel News and Research

Further Reading

Increased stress hormones accelerate breast cancer metastasis

Hypertension drug may improve effectiveness of ovarian cancer treatment

Clinigen, Accord Healthcare extend exclusive European clinical trial supply agreement

Study uncovers how tumors backfire on neoadjuvant chemotherapy

Study assesses safety and efficacy of new treatment for pancreatic cancer

New substance could improve efficacy of established breast cancer treatments

Two genomic tests help identify most effective treatment for breast cancer patients

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Study findings could set new standard of care for advanced anal cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Immunotherapy trial offers new hope for people with aggressive breast cancer

Breast cancer survival could be extended with two new drug combinations

Two major studies on canine cancers may provide clues on human cancers

Study: Chemotherapy drugs may promote muscle mitochondrial dysfunction

Researchers take first steps in developing 'paintable' chemotherapy for melanoma

Researchers discover novel targeting agents to prevent cancer metastasis

FDA approves new 5 mm diameter drug-eluting stent from Cook Medical

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

Researchers develop better options to treat peripheral artery disease

One Health, One Mission: The World Organisation for Animal Health on the AMR Frontline

Uniting Against Resistance: The World Health Organization for World Antimicrobial Awareness Week 2023

Tackling Antimicrobial Resistance: A Conversation with Dr. Beverley Isherwood

Latest News